1	24	34	Background	background	NNP	_	_	B-cesDoc	B-text	B-body	B-div	B-head	_	_
2	43	50	Primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
3	51	58	Sjögren	sjögren	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
4	58	60	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
5	61	69	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
6	70	71	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
7	71	72	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
8	72	73	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
9	73	75	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
10	75	76	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
11	77	79	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
12	80	81	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
13	82	90	systemic	systemic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
14	99	109	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
15	110	118	disorder	disorder	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
16	119	132	characterized	characterize	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
17	133	135	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
18	136	139	dry	dry	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
19	140	144	eyes	eye	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
20	153	154	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
21	154	174	keratoconjunctivitis	keratoconjunctivitis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
22	175	180	sicca	sicca	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
23	180	181	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
24	181	182	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
25	183	186	dry	dry	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
26	187	192	mouth	mouth	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
27	193	194	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
28	194	204	xerostomia	xerostomium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
29	204	205	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
30	206	208	as	as	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
31	217	221	well	well	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
32	222	224	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
33	225	236	involvement	involvement	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
34	237	239	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
35	240	245	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
36	246	254	exocrine	exocrine	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
37	255	261	glands	gland	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
38	261	262	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
39	263	268	While	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
40	269	270	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
41	270	271	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
42	271	273	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
43	274	276	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
44	285	294	typically	typically	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
45	295	305	considered	consider	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
46	306	308	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
47	309	319	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
48	320	333	exocrinopathy	exocrinopathy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
49	333	334	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
50	335	338	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
51	347	353	immune	immune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
52	354	365	destruction	destruction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
53	366	369	can	can	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
54	370	375	often	often	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
55	376	382	extend	extend	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
56	383	385	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
57	386	392	affect	affect	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
58	393	405	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
59	414	420	organs	organ	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
60	420	421	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
61	422	428	Around	around	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
62	429	431	25	25	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
63	432	433	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
64	434	436	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
65	437	445	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
66	446	450	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
67	451	452	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
68	452	453	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
69	453	455	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
70	456	459	can	can	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
71	460	467	present	present	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
72	468	472	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
73	481	492	involvement	involvement	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
74	493	495	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
75	496	501	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
76	502	508	organs	organ	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
77	509	513	such	such	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
78	514	516	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
79	517	520	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
80	521	528	thyroid	thyroid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
81	528	529	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
82	530	537	central	central	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
83	546	553	nervous	nervous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
84	554	560	system	system	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
85	560	561	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
86	562	567	lungs	lung	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
87	567	568	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
88	569	575	kidney	kidney	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
89	576	579	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
90	580	585	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
91	585	586	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
92	587	590	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
93	591	602	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
94	603	605	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
95	614	619	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
96	620	627	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
97	628	631	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
98	632	633	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
99	633	634	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
100	634	636	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
101	637	640	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
102	641	650	suggested	suggest	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
103	651	655	more	more	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
104	656	660	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
105	661	663	40	40	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
106	664	669	years	year	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
107	670	673	ago	ago	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
108	682	683	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
109	684	685	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
110	686	687	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
111	688	689	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
112	690	695	While	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
113	696	701	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
114	702	713	involvement	involvement	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
115	714	716	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
116	717	718	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
117	718	719	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
118	719	721	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
119	722	725	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
120	726	730	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
121	731	741	considered	consider	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
122	750	751	""	""	''	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
123	751	755	rare	rare	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
124	755	756	""	""	''	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
125	757	758	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
126	759	760	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
127	761	762	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
128	763	767	only	only	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
129	768	769	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
130	770	773	few	few	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
131	774	782	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
132	783	790	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
133	791	803	specifically	specifically	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
134	812	819	address	address	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
135	820	824	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
136	825	837	complication	complication	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
137	838	841	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
138	842	850	evaluate	evaluate	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
139	851	854	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
140	855	866	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
141	867	869	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
142	878	883	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
143	884	892	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
144	893	898	tests	test	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
145	899	912	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
146	913	917	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
147	918	921	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
148	922	930	severity	severity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
149	931	933	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
150	942	943	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
151	943	944	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
152	944	946	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
153	947	948	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
154	949	950	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
155	951	952	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
156	953	954	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
157	955	956	6	6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
158	957	958	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
159	959	960	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
160	969	974	Liver	liver	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
161	975	983	diseases	disease	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
162	984	994	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
163	995	999	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
164	1000	1001	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
165	1001	1002	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
166	1002	1004	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
167	1005	1012	include	include	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
168	1013	1020	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
169	1029	1036	biliary	biliary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
170	1037	1046	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
171	1047	1048	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
172	1048	1051	PBC	pbc	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
173	1051	1052	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
174	1052	1053	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
175	1053	1063	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
176	1064	1075	cholangitis	cholangitis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
177	1076	1077	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
178	1078	1079	8	8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
179	1080	1081	9	9	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
180	1082	1084	10	10	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
181	1085	1086	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
182	1087	1088	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
183	1097	1107	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
184	1108	1117	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
185	1118	1119	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
186	1120	1121	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
187	1122	1123	6	6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
188	1124	1125	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
189	1126	1127	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
190	1128	1133	viral	viral	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
191	1134	1143	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
192	1144	1145	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
193	1145	1146	B	b	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
194	1147	1150	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
195	1151	1152	C	c	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
196	1152	1153	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
197	1154	1155	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
198	1164	1166	11	11	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
199	1167	1169	12	12	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
200	1170	1172	13	13	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
201	1173	1175	14	14	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
202	1176	1178	15	15	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
203	1179	1181	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
204	1182	1184	17	17	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
205	1185	1187	18	18	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
206	1188	1190	19	19	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
207	1191	1193	20	20	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
208	1194	1196	21	21	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
209	1197	1198	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
210	1199	1200	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
211	1201	1211	sclerosing	sclerose	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
212	1212	1223	cholangitis	cholangitis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
213	1232	1233	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
214	1234	1236	22	22	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
215	1237	1238	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
216	1239	1240	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
217	1241	1244	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
218	1245	1252	nodular	nodular	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
219	1253	1265	regenerative	regenerative	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
220	1266	1277	hyperplasia	hyperplasium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
221	1278	1279	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
222	1280	1282	23	23	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
223	1283	1284	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
224	1285	1286	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
225	1287	1289	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
226	1298	1306	addition	addition	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
227	1306	1307	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
228	1308	1315	chronic	chronic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
229	1316	1327	lymphocytic	lymphocytic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
230	1328	1340	sialadenitis	sialadenitis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
231	1341	1344	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
232	1345	1349	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
233	1350	1355	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
234	1364	1366	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
235	1367	1375	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
236	1376	1380	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
237	1381	1390	different	different	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
238	1391	1396	types	type	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
239	1397	1399	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
240	1400	1405	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
241	1406	1415	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
242	1416	1417	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
243	1418	1420	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
244	1421	1423	17	17	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
245	1432	1434	18	18	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
246	1435	1437	19	19	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
247	1438	1440	20	20	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
248	1441	1443	21	21	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
249	1444	1446	22	22	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
250	1447	1449	23	23	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
251	1450	1452	24	24	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
252	1453	1454	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
253	1455	1456	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
254	1465	1467	We	we	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
255	1468	1474	report	report	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
256	1475	1478	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
257	1479	1486	results	result	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
258	1487	1489	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
259	1490	1491	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
260	1492	1498	review	review	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
261	1499	1501	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
262	1502	1507	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
263	1508	1518	undertaken	undertake	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
264	1519	1521	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
265	1530	1539	determine	determine	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
266	1540	1543	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
267	1544	1554	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
268	1555	1557	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
269	1558	1566	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
270	1567	1572	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
271	1573	1581	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
272	1582	1587	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
273	1596	1597	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
274	1597	1601	LFTs	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
275	1601	1602	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
276	1603	1606	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
277	1607	1612	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
278	1613	1620	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
279	1621	1623	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
280	1624	1632	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
281	1633	1637	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
282	1638	1639	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
283	1639	1640	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
284	1640	1642	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
285	1643	1651	referred	refer	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
286	1652	1654	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
287	1663	1664	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
288	1665	1673	tertiary	tertiary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
289	1674	1678	care	care	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
290	1679	1685	center	center	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
291	1686	1689	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
292	1690	1693	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
293	1694	1705	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
294	1706	1708	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
295	1709	1717	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
296	1718	1722	LFTs	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
297	1731	1735	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
298	1736	1741	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
299	1742	1750	systemic	systemic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
300	1751	1759	features	feature	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
301	1760	1763	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
302	1764	1776	autoimmunity	autoimmunity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
303	1777	1784	markers	marker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
304	1785	1787	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
305	1796	1797	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
306	1797	1798	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
307	1798	1800	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
308	1800	1801	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
309	1824	1831	Methods	method	NNP	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
310	1851	1862	Statistical	statistical	NNP	_	_	I-cesDoc	I-text	I-body	I-div	B-head	_	_
311	1863	1871	analysis	analysis	NN	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
312	1882	1885	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
313	1886	1897	statistical	statistical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
314	1898	1906	analysis	analysis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
315	1907	1915	included	include	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
316	1916	1927	descriptive	descriptive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
317	1928	1936	measures	measure	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
318	1947	1948	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
319	1948	1953	means	means	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
320	1953	1954	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
321	1955	1963	standard	standard	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
322	1964	1974	deviations	deviation	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
323	1975	1978	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
324	1979	1985	ranges	range	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
325	1985	1986	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
326	1986	1987	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
327	1988	1998	Comparison	comparison	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
328	1999	2001	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
329	2012	2019	results	result	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
330	2020	2022	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
331	2023	2031	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
332	2032	2036	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
333	2037	2040	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
334	2041	2048	without	without	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
335	2049	2054	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
336	2055	2062	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
337	2063	2066	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
338	2077	2081	done	do	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
339	2082	2087	using	use	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
340	2088	2095	t-tests	t-test	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
341	2096	2098	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
342	2099	2109	continuous	continuous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
343	2110	2119	variables	variable	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
344	2120	2123	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
345	2124	2130	Fisher	fisher	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
346	2130	2132	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
347	2143	2148	exact	exact	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
348	2149	2153	test	test	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
349	2154	2156	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
350	2157	2158	x	x	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
351	2158	2159	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
352	2160	2163	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
353	2164	2173	categoric	categoric	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
354	2174	2182	measures	measure	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
355	2182	2183	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
356	2215	2222	Results	result	NNS	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
357	2231	2233	Of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
358	2234	2237	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
359	2238	2241	115	115	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
360	2242	2248	charts	chart	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
361	2249	2257	reviewed	review	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
362	2257	2258	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
363	2259	2261	73	73	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
364	2262	2267	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
365	2268	2269	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
366	2269	2271	55	55	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
367	2272	2277	women	woman	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
368	2278	2281	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
369	2282	2284	18	18	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
370	2293	2296	men	man	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
371	2296	2297	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
372	2298	2304	median	median	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
373	2305	2308	age	age	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
374	2309	2311	53	53	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
375	2311	2312	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
376	2313	2322	fulfilled	fulfill	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
377	2323	2327	EECC	eecc	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
378	2328	2331	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
379	2332	2333	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
380	2333	2334	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
381	2334	2336	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
382	2337	2340	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
383	2341	2345	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
384	2354	2363	initially	initially	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
385	2364	2372	included	include	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
386	2373	2376	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
387	2377	2385	analysis	analysis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
388	2385	2386	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
389	2387	2389	Of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
390	2390	2393	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
391	2394	2396	73	73	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
392	2397	2405	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
393	2405	2406	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
394	2407	2408	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
395	2409	2411	54	54	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
396	2411	2412	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
397	2421	2423	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
398	2424	2428	them	them	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
399	2429	2430	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
400	2430	2432	40	40	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
401	2433	2441	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
402	2441	2442	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
403	2443	2447	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
404	2448	2451	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
405	2452	2453	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
406	2454	2462	salivary	salivary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
407	2463	2468	gland	gland	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
408	2469	2475	biopsy	biopsy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
409	2484	2493	performed	perform	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
410	2493	2494	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
411	2495	2497	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
412	2498	2501	all	all	PDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
413	2502	2507	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
414	2508	2516	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
415	2516	2517	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
416	2518	2521	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
417	2522	2528	biopsy	biopsy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
418	2529	2538	confirmed	confirm	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
419	2539	2542	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
420	2551	2560	diagnosis	diagnosis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
421	2561	2563	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
422	2564	2571	Sjögren	sjögren	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
423	2571	2573	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
424	2574	2582	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
425	2582	2583	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
426	2584	2587	All	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
427	2588	2596	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
428	2597	2604	studied	study	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
429	2605	2608	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
430	2617	2626	objective	objective	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
431	2627	2635	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
432	2636	2638	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
433	2639	2640	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
434	2640	2641	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
435	2641	2643	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
436	2643	2644	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
437	2645	2654	including	include	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
438	2655	2675	keratoconjunctivitis	keratoconjunctivitis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
439	2684	2689	sicca	sicca	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
440	2689	2690	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
441	2691	2699	positive	positive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
442	2700	2706	labial	labial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
443	2707	2715	salivary	salivary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
444	2716	2721	gland	gland	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
445	2722	2728	biopsy	biopsy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
446	2728	2729	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
447	2738	2752	autoantibodies	autoantibody	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
448	2753	2756	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
449	2756	2757	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
450	2757	2759	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
451	2760	2768	salivary	salivary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
452	2769	2774	gland	gland	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
453	2775	2787	hypofunction	hypofunction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
454	2787	2788	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
455	2789	2791	We	we	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
456	2800	2808	excluded	exclude	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
457	2809	2814	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
458	2815	2823	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
459	2824	2831	without	without	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
460	2832	2837	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
461	2838	2847	objective	objective	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
462	2848	2856	criteria	criterion	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
463	2857	2859	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
464	2868	2869	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
465	2869	2870	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
466	2870	2872	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
467	2873	2876	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
468	2877	2881	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
469	2882	2887	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
470	2888	2891	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
471	2892	2895	did	do	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
472	2896	2899	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
473	2900	2907	fulfill	fulfill	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
474	2908	2912	EECC	eecc	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
475	2913	2921	criteria	criterion	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
476	2921	2922	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
477	2931	2934	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
478	2935	2939	mean	mean	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
479	2940	2943	age	age	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
480	2944	2946	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
481	2947	2951	time	time	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
482	2952	2954	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
483	2955	2960	onset	onset	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
484	2961	2963	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
485	2964	2971	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
486	2972	2975	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
487	2976	2978	45	45	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
488	2979	2980	±	±	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
489	2981	2985	20.5	20.5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
490	2994	2999	years	year	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
491	3000	3003	old	old	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
492	3004	3007	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
493	3008	3015	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
494	3016	3024	duration	duration	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
495	3025	3028	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
496	3029	3032	4.9	4.9	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
497	3033	3038	years	year	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
498	3039	3040	±	±	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
499	3041	3044	4.5	4.5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
500	3045	3050	years	year	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
501	3059	3060	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
502	3060	3064	mean	mean	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
503	3065	3066	±	±	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
504	3067	3072	range	range	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
505	3072	3073	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
506	3073	3074	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
507	3075	3080	Liver	liver	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
508	3081	3089	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
509	3090	3095	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
510	3096	3099	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
511	3100	3104	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
512	3105	3115	determined	determine	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
513	3116	3118	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
514	3127	3129	59	59	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
515	3130	3138	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
516	3139	3140	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
517	3140	3144	80.8	80.8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
518	3145	3146	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
519	3146	3147	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
520	3148	3151	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
521	3152	3160	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
522	3161	3166	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
523	3167	3175	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
524	3176	3181	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
525	3182	3186	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
526	3195	3200	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
527	3201	3203	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
528	3204	3206	29	29	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
529	3207	3209	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
530	3210	3213	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
531	3214	3216	59	59	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
532	3217	3225	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
533	3226	3227	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
534	3227	3231	49.1	49.1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
535	3232	3233	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
536	3233	3234	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
537	3234	3235	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
538	3236	3243	Further	further	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
539	3244	3252	analysis	analysis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
540	3261	3264	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
541	3265	3269	then	then	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
542	3270	3280	undertaken	undertake	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
543	3281	3283	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
544	3284	3289	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
545	3290	3298	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
546	3299	3301	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
547	3302	3306	whom	whom	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
548	3307	3311	LFTs	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
549	3312	3315	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
550	3316	3320	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
551	3329	3337	measured	measure	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
552	3337	3338	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
553	3339	3342	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
554	3343	3351	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
555	3352	3355	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
556	3356	3366	laboratory	laboratory	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
557	3367	3382	characteristics	characteristic	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
558	3383	3385	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
559	3394	3399	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
560	3400	3408	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
561	3409	3412	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
562	3413	3418	shown	show	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
563	3419	3421	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
564	3422	3428	Tables	table	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
565	3429	3430	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
566	3430	3433	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
567	3434	3435	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
568	3435	3436	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
569	3445	3448	For	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
570	3449	3454	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
571	3455	3457	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
572	3458	3466	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
573	3467	3474	studied	study	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
574	3474	3475	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
575	3476	3484	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
576	3485	3489	LFTs	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
577	3490	3494	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
578	3495	3499	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
579	3508	3514	common	common	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
580	3515	3519	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
581	3520	3523	any	any	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
582	3524	3529	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
583	3530	3539	potential	potential	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
584	3540	3552	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
585	3553	3561	features	feature	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
586	3562	3564	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
587	3573	3575	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
588	3575	3576	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
589	3577	3585	Clinical	clinical	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
590	3586	3594	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
591	3595	3597	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
592	3598	3603	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
593	3604	3611	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
594	3611	3612	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
595	3613	3620	defined	define	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
596	3621	3623	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
597	3624	3631	methods	method	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
598	3640	3647	section	section	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
599	3647	3648	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
600	3649	3652	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
601	3653	3658	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
602	3659	3661	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
603	3662	3664	12	12	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
604	3665	3673	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
605	3674	3675	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
606	3675	3679	20.3	20.3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
607	3679	3680	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
608	3680	3681	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
609	3681	3682	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
610	3683	3686	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
611	3687	3689	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
612	3690	3694	whom	whom	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
613	3695	3698	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
614	3707	3715	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
615	3716	3721	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
616	3722	3730	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
617	3731	3736	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
618	3736	3737	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
619	3738	3741	Two	two	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
620	3742	3748	deaths	death	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
621	3749	3757	occurred	occur	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
622	3758	3760	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
623	3761	3764	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
624	3773	3783	population	population	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
625	3784	3791	studied	study	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
626	3791	3792	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
627	3793	3797	both	both	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
628	3798	3808	attributed	attribute	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
629	3809	3811	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
630	3812	3817	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
631	3818	3825	failure	failure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
632	3825	3826	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
633	3827	3829	An	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
634	3838	3848	additional	additional	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
635	3849	3856	patient	patient	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
636	3857	3865	required	require	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
637	3866	3867	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
638	3868	3873	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
639	3874	3884	transplant	transplant	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
640	3884	3885	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
641	3886	3888	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
642	3889	3892	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
643	3901	3906	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
644	3906	3907	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
645	3908	3911	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
646	3912	3921	diagnosis	diagnosis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
647	3922	3924	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
648	3925	3926	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
649	3926	3927	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
650	3927	3929	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
651	3930	3939	antedated	antedate	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
652	3940	3943	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
653	3944	3949	onset	onset	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
654	3950	3952	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
655	3953	3958	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
656	3967	3974	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
657	3975	3977	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
658	3978	3981	its	its	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
659	3982	3991	diagnosis	diagnosis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
660	3991	3992	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
661	3993	4000	Markers	marker	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
662	4001	4003	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
663	4004	4009	viral	viral	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
664	4010	4019	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
665	4019	4020	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
666	4029	4035	sought	seek	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
667	4036	4038	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
668	4039	4041	39	39	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
669	4042	4050	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
670	4050	4051	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
671	4052	4056	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
672	4057	4062	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
673	4063	4067	only	only	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
674	4068	4070	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
675	4071	4072	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
676	4072	4073	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
677	4074	4077	Two	two	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
678	4078	4086	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
679	4095	4102	carried	carry	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
680	4103	4106	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
681	4107	4114	surface	surface	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
682	4115	4122	antigen	antigen	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
683	4123	4125	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
684	4126	4135	hepatitis	hepatitis	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
685	4136	4137	B	b	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
686	4138	4143	virus	virus	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
687	4144	4147	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
688	4148	4151	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
689	4160	4163	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
690	4164	4174	antibodies	antibody	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
691	4175	4177	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
692	4178	4187	hepatitis	hepatitis	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
693	4188	4189	C	c	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
694	4190	4195	virus	virus	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
695	4195	4196	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
696	4197	4199	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
697	4200	4201	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
698	4202	4207	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
699	4208	4214	biopsy	biopsy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
700	4215	4217	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
701	4218	4219	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
702	4228	4235	patient	patient	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
703	4236	4239	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
704	4240	4246	lacked	lack	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
705	4247	4258	serological	serological	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
706	4259	4266	markers	marker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
707	4267	4270	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
708	4271	4280	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
709	4289	4296	viruses	virus	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
710	4296	4297	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
711	4298	4307	hepatitis	hepatitis	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
712	4308	4309	B	b	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
713	4310	4315	virus	virus	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
714	4316	4319	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
715	4320	4328	detected	detect	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
716	4329	4331	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
717	4341	4343	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
718	4344	4348	situ	situ	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	I-hi
719	4349	4362	hybridization	hybridization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
720	4362	4363	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
721	4372	4376	Risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
722	4377	4384	factors	factor	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
723	4385	4388	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
724	4389	4394	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
725	4395	4402	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
726	4403	4407	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
727	4408	4418	identified	identify	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
728	4419	4421	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
729	4422	4424	40	40	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
730	4424	4425	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
731	4426	4428	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
732	4437	4440	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
733	4441	4449	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
734	4450	4454	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
735	4455	4463	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
736	4464	4469	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
737	4470	4478	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
738	4479	4484	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
739	4485	4488	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
740	4489	4492	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
741	4501	4510	described	describe	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
742	4511	4513	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
743	4514	4519	Table	table	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
744	4520	4521	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
745	4521	4522	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
746	4523	4525	No	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
747	4526	4537	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
748	4538	4542	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
749	4543	4550	tobacco	tobacco	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
750	4551	4554	use	use	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
751	4555	4558	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
752	4567	4572	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
753	4572	4573	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
754	4574	4578	Only	only	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
755	4579	4580	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
756	4581	4589	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
757	4590	4593	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
758	4594	4604	documented	document	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
759	4605	4613	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
760	4614	4616	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
761	4617	4624	tobacco	tobacco	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
762	4633	4644	consumption	consumption	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
763	4644	4645	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
764	4646	4648	We	we	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
765	4649	4654	found	find	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
766	4655	4657	no	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
767	4658	4669	significant	significant	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
768	4670	4681	differences	difference	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
769	4682	4684	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
770	4685	4689	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
771	4698	4705	factors	factor	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
772	4706	4709	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
773	4710	4718	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
774	4719	4724	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
775	4725	4733	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
776	4734	4739	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
777	4740	4745	among	among	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
778	4746	4754	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
779	4763	4767	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
780	4768	4770	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
781	4771	4778	without	without	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
782	4779	4786	hepatic	hepatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
783	4787	4798	involvement	involvement	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
784	4798	4799	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
785	4800	4809	Therefore	therefore	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
786	4809	4810	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
787	4811	4813	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
788	4814	4816	60	60	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
789	4816	4817	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
790	4818	4820	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
791	4829	4832	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
792	4833	4841	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
793	4842	4846	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
794	4847	4850	sub	sub	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
795	4851	4859	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
796	4860	4862	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
797	4863	4871	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
798	4872	4880	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
799	4881	4883	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
800	4892	4897	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
801	4898	4905	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
802	4905	4906	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
803	4907	4909	no	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
804	4910	4915	clear	clear	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
805	4916	4927	explanation	explanation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
806	4928	4931	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
807	4932	4935	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
808	4936	4944	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
809	4945	4949	LFTs	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
810	4958	4961	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
811	4962	4967	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
812	4967	4968	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
813	4969	4975	except	except	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
814	4976	4979	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
815	4980	4983	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
816	4984	4995	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
817	4996	5000	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
818	5001	5002	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
819	5002	5003	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
820	5003	5005	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
821	5005	5006	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
822	5015	5018	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
823	5019	5026	pattern	pattern	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
824	5027	5029	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
825	5030	5041	biochemical	biochemical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
826	5042	5047	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
827	5048	5061	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
828	5062	5065	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
829	5074	5080	mainly	mainly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
830	5081	5095	hepatocellular	hepatocellular	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
831	5096	5097	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
832	5097	5104	defined	define	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
833	5105	5107	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
834	5108	5119	predominant	predominant	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
835	5120	5128	increase	increase	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
836	5129	5131	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
837	5140	5143	AST	ast	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
838	5144	5147	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
839	5147	5148	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
840	5148	5150	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
841	5151	5154	ALT	alt	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
842	5155	5157	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
843	5158	5168	comparison	comparison	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
844	5169	5173	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
845	5174	5176	AP	ap	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
846	5177	5180	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
847	5180	5181	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
848	5181	5183	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
849	5184	5194	bilirubins	bilirubin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
850	5194	5195	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
851	5196	5198	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
852	5207	5209	11	11	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
853	5210	5215	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
854	5215	5216	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
855	5217	5228	cholestatic	cholestatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
856	5229	5230	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
857	5230	5237	defined	define	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
858	5238	5240	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
859	5241	5252	predominant	predominant	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
860	5253	5261	increase	increase	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
861	5262	5264	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
862	5273	5275	AP	ap	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
863	5276	5279	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
864	5279	5280	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
865	5280	5282	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
866	5283	5293	bilirubins	bilirubin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
867	5294	5302	compared	compare	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
868	5303	5307	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
869	5308	5311	AST	ast	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
870	5312	5315	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
871	5315	5316	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
872	5316	5318	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
873	5319	5322	ALT	alt	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
874	5322	5323	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
875	5324	5326	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
876	5327	5328	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
877	5329	5332	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
878	5341	5346	mixed	mix	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
879	5347	5348	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
880	5348	5356	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
881	5357	5359	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
882	5360	5364	both	both	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
883	5365	5376	cholestatic	cholestatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
884	5377	5380	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
885	5381	5395	hepatocellular	hepatocellular	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
886	5404	5410	damage	damage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
887	5410	5411	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
888	5412	5414	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
889	5415	5416	8	8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
890	5417	5422	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
891	5422	5423	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
892	5424	5437	Abnormalities	abnormality	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
893	5438	5442	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
894	5443	5453	persistent	persistent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
895	5454	5455	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
896	5455	5462	present	present	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
897	5471	5473	on	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
898	5474	5479	every	every	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
899	5480	5488	occasion	occasion	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
900	5489	5493	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
901	5494	5502	measured	measure	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
902	5503	5507	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
903	5508	5512	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
904	5513	5517	once	once	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
905	5517	5518	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
906	5519	5521	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
907	5522	5524	19	19	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
908	5533	5541	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
909	5542	5543	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
910	5543	5547	65.5	65.5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
911	5547	5548	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
912	5549	5551	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
913	5552	5557	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
914	5558	5562	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
915	5563	5571	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
916	5572	5576	LFTs	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
917	5576	5577	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
918	5577	5578	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
919	5579	5591	intermittent	intermittent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
920	5600	5601	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
921	5601	5609	presence	presence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
922	5610	5612	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
923	5613	5616	LFT	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
924	5617	5630	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
925	5631	5634	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
926	5635	5638	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
927	5639	5644	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
928	5645	5647	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
929	5648	5651	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
930	5660	5674	determinations	determination	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
931	5674	5675	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
932	5676	5678	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
933	5679	5680	9	9	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
934	5681	5682	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
935	5682	5684	31	31	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
936	5684	5685	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
937	5685	5686	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
938	5687	5690	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
939	5691	5693	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
940	5694	5697	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
941	5698	5702	case	case	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
942	5703	5704	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
943	5704	5707	3.5	3.5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
944	5707	5708	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
945	5708	5709	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
946	5710	5715	there	there	EX	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
947	5716	5719	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
948	5728	5732	only	only	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
949	5733	5736	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
950	5737	5750	determination	determination	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
951	5751	5753	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
952	5754	5759	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
953	5760	5768	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
954	5769	5774	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
955	5774	5775	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
956	5776	5779	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
957	5780	5787	pattern	pattern	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
958	5796	5798	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
959	5799	5804	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
960	5805	5811	enzyme	enzyme	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
961	5812	5825	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
962	5826	5828	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
963	5829	5834	shown	show	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
964	5835	5837	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
965	5838	5844	Figure	figure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
966	5845	5846	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
967	5846	5847	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
968	5848	5852	None	none	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
969	5853	5855	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
970	5864	5867	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
971	5868	5876	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
972	5877	5881	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
973	5882	5890	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
974	5891	5896	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
975	5897	5905	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
976	5906	5911	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
977	5912	5915	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
978	5924	5932	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
979	5933	5941	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
980	5942	5944	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
981	5945	5951	muscle	muscle	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
982	5952	5963	involvement	involvement	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
983	5964	5968	that	that	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
984	5969	5974	could	could	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
985	5975	5982	explain	explain	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
986	5991	5994	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
987	5995	5999	high	high	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
988	6000	6006	levels	level	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
989	6007	6009	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
990	6010	6028	amino-transferases	amino-transferase	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
991	6028	6029	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
992	6030	6038	Activity	activity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
993	6039	6041	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
994	6042	6045	CPK	cpk	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
995	6046	6048	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
996	6057	6065	aldolase	aldolase	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
997	6066	6069	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
998	6070	6073	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
999	6074	6082	elevated	elevate	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1000	6083	6087	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1001	6088	6096	measured	measure	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1002	6097	6099	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1003	6100	6102	15	15	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1004	6103	6105	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1005	6106	6109	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1006	6110	6112	29	29	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1007	6121	6129	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1008	6130	6134	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1009	6135	6143	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1010	6144	6149	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1011	6150	6158	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1012	6159	6164	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1013	6164	6165	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1014	6174	6192	Anti-mitochondrial	anti-mitochondrial	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1015	6193	6203	antibodies	antibody	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1016	6204	6205	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1017	6205	6208	AMA	ama	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1018	6208	6209	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1019	6210	6213	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1020	6214	6225	anti-smooth	anti-smooth	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1021	6226	6232	muscle	muscle	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1022	6241	6251	antibodies	antibody	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1023	6252	6253	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1024	6253	6257	ASMA	asma	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1025	6257	6258	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1026	6259	6263	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1027	6264	6270	sought	seek	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1028	6271	6273	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1029	6274	6275	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1030	6276	6284	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1031	6284	6285	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1032	6286	6290	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1033	6291	6299	positive	positive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1034	6308	6312	ASMA	asma	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1035	6313	6315	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1036	6316	6317	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1037	6317	6318	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1038	6327	6330	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1039	6331	6342	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1040	6343	6345	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1041	6346	6354	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1042	6355	6360	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1043	6361	6369	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1044	6370	6375	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1045	6376	6380	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1046	6389	6394	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1047	6395	6407	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1048	6408	6416	features	feature	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1049	6417	6419	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1050	6420	6421	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1051	6421	6422	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1052	6422	6424	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1053	6425	6427	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1054	6428	6433	shown	show	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1055	6434	6436	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1056	6437	6443	Figure	figure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1057	6444	6445	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1058	6445	6446	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1059	6455	6463	Patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1060	6464	6468	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1061	6469	6477	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1062	6478	6483	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1063	6484	6492	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1064	6493	6498	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1065	6499	6503	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1066	6504	6508	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1067	6517	6523	likely	likely	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1068	6524	6526	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1069	6527	6531	have	have	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1070	6532	6536	lung	lung	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1071	6536	6537	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1072	6538	6544	kidney	kidney	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1073	6545	6547	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1074	6548	6561	hematological	hematological	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1075	6570	6584	manifestations	manifestation	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1076	6584	6585	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1077	6586	6590	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1078	6591	6599	compared	compare	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1079	6600	6602	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1080	6603	6610	Sjögren	sjögren	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1081	6610	6612	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1082	6613	6621	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1083	6622	6629	without	without	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1084	6638	6643	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1085	6644	6651	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1086	6651	6652	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1087	6653	6661	Presence	presence	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1088	6662	6664	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1089	6665	6670	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1090	6671	6683	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1091	6684	6692	features	feature	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1092	6693	6695	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1093	6704	6705	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1094	6705	6706	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1095	6706	6708	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1096	6709	6712	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1097	6713	6716	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1098	6717	6727	influenced	influence	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1099	6728	6730	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1100	6731	6741	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1101	6742	6744	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1102	6745	6750	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1103	6759	6767	diseases	disease	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1104	6767	6768	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1105	6777	6786	Regarding	regard	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1106	6787	6797	laboratory	laboratory	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1107	6798	6802	test	test	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1108	6803	6810	results	result	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1109	6810	6811	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1110	6812	6820	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1111	6821	6825	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1112	6826	6831	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1113	6840	6847	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1114	6848	6852	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1115	6853	6857	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1116	6858	6864	likely	likely	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1117	6865	6867	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1118	6868	6872	have	have	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1119	6873	6875	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1120	6876	6884	elevated	elevated	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1121	6885	6898	sedimentation	sedimentation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1122	6907	6911	rate	rate	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1123	6912	6914	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1124	6915	6919	some	some	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1125	6920	6925	point	point	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1126	6926	6932	during	during	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1127	6933	6936	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1128	6937	6943	course	course	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1129	6944	6946	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1130	6947	6952	their	their	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1131	6953	6960	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1132	6960	6961	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1133	6962	6963	A	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1134	6972	6980	positive	positive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1135	6981	6986	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1136	6986	6989	ENA	ena	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1137	6990	6991	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1138	6991	6996	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1139	6996	6998	Ro	ro	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1140	6998	6999	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1141	7000	7005	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1142	7005	7007	Ro	ro	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1143	7007	7008	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1144	7008	7010	La	la	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1145	7010	7011	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1146	7012	7015	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1147	7015	7016	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1148	7016	7018	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1149	7019	7024	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1150	7024	7027	RNP	rnp	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1151	7027	7028	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1152	7037	7040	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1153	7041	7045	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1154	7046	7056	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1155	7057	7061	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1156	7062	7064	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1157	7065	7074	increased	increased	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1158	7075	7085	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1159	7086	7088	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1160	7097	7105	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1161	7106	7111	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1162	7112	7120	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1163	7121	7126	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1164	7127	7128	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1165	7128	7134	Figure	figure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1166	7135	7136	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1167	7136	7137	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1168	7137	7138	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1169	7139	7142	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1170	7143	7149	sample	sample	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1171	7150	7153	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1172	7162	7165	too	too	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1173	7166	7171	small	small	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1174	7172	7174	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1175	7175	7184	determine	determine	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1176	7185	7192	whether	whether	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1177	7193	7194	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1178	7195	7203	specific	specific	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1179	7204	7207	ENA	ena	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1180	7208	7211	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1181	7220	7230	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1182	7231	7235	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1183	7236	7241	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1184	7242	7249	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1185	7249	7250	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1186	7251	7256	Other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1187	7257	7264	markers	marker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1188	7265	7267	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1189	7268	7276	systemic	systemic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1190	7285	7297	inflammation	inflammation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1191	7298	7300	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1192	7301	7313	autoimmunity	autoimmunity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1193	7314	7317	did	do	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1194	7318	7321	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1195	7322	7331	correlate	correlate	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1196	7332	7336	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1197	7337	7340	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1198	7349	7357	presence	presence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1199	7358	7360	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1200	7361	7368	absence	absence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1201	7369	7371	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1202	7372	7375	LFT	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1203	7376	7389	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1204	7389	7390	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1205	7399	7404	Liver	liver	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1206	7405	7413	biopsies	biopsy	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1207	7413	7414	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1208	7415	7419	done	do	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1209	7420	7422	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1210	7423	7424	8	8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1211	7425	7433	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1212	7433	7434	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1213	7435	7444	disclosed	disclose	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1214	7445	7455	post-viral	post-viral	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1215	7464	7471	chronic	chronic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1216	7472	7478	active	active	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1217	7479	7488	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1218	7489	7490	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1219	7490	7491	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1220	7491	7492	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1221	7492	7493	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1222	7494	7505	cryptogenic	cryptogenic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1223	7506	7515	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1224	7516	7517	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1225	7517	7518	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1226	7518	7519	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1227	7519	7520	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1228	7529	7532	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1229	7533	7536	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1230	7537	7541	case	case	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1231	7542	7546	each	each	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1232	7547	7549	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1233	7550	7560	post-viral	post-viral	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1234	7561	7570	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1235	7570	7571	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1236	7572	7581	alcoholic	alcoholic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1237	7590	7599	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1238	7599	7600	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1239	7601	7604	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1240	7605	7615	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1241	7616	7625	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1242	7625	7626	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1243	7649	7659	Discussion	discussion	NNP	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
1244	7668	7670	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1245	7671	7675	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1246	7676	7681	group	group	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1247	7682	7684	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1248	7685	7692	Sjögren	sjögren	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1249	7692	7694	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1250	7695	7703	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1251	7704	7708	seen	see	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1252	7709	7711	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1253	7712	7713	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1254	7714	7722	tertiary	tertiary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1255	7731	7735	care	care	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1256	7736	7742	center	center	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1257	7742	7743	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1258	7744	7752	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1259	7753	7758	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1260	7759	7767	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1261	7768	7773	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1262	7774	7778	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1263	7779	7784	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1264	7785	7787	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1265	7788	7790	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1266	7799	7800	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1267	7801	7807	common	common	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1268	7808	7820	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1269	7821	7828	feature	feature	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1270	7829	7831	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1271	7832	7833	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1272	7833	7834	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1273	7834	7836	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1274	7836	7837	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1275	7838	7841	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1276	7842	7852	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1277	7853	7855	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1278	7864	7868	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1279	7869	7880	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1280	7881	7884	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1281	7885	7890	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1282	7891	7893	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1283	7894	7896	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1284	7897	7903	higher	higher	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1285	7904	7906	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1286	7907	7910	our	our	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1287	7911	7916	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1288	7917	7921	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1289	7930	7932	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1290	7933	7938	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1291	7939	7947	previous	previous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1292	7948	7954	series	series	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1293	7955	7956	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1294	7957	7958	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1295	7959	7960	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1296	7961	7962	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1297	7963	7964	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1298	7965	7966	6	6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1299	7967	7968	7	7	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1300	7969	7970	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1301	7971	7972	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1302	7973	7976	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1303	7977	7981	true	true	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1304	7990	8000	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1305	8001	8006	could	could	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1306	8007	8009	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1307	8010	8014	even	even	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1308	8015	8021	higher	higher	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1309	8022	8027	since	since	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1310	8028	8033	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1311	8034	8040	enzyme	enzyme	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1312	8041	8049	profiles	profile	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1313	8058	8062	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1314	8063	8066	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1315	8067	8071	done	do	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1316	8072	8074	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1317	8075	8078	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1318	8079	8087	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1319	8087	8088	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1320	8089	8092	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1321	8093	8103	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1322	8104	8113	suggested	suggest	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1323	8114	8116	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1324	8125	8133	previous	previous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1325	8134	8141	reports	report	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1326	8142	8148	ranges	range	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1327	8149	8153	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1328	8154	8155	6	6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1329	8156	8158	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1330	8159	8161	58	58	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1331	8162	8163	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1332	8163	8164	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1333	8165	8168	but	but	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1334	8169	8172	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1335	8173	8183	definition	definition	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1336	8192	8194	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1337	8195	8202	hepatic	hepatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1338	8203	8210	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1339	8211	8217	varies	vary	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1340	8218	8222	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1341	8223	8226	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1342	8227	8237	unspecific	unspecific	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1343	8238	8239	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1344	8239	8243	e.g.	e.g.	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1345	8252	8264	hepatomegaly	hepatomegaly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1346	8264	8265	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1347	8266	8268	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1348	8269	8273	well	well	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1349	8274	8280	proven	prove	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1350	8281	8286	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1351	8287	8289	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1352	8290	8295	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1353	8296	8303	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1354	8304	8305	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1355	8306	8307	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1356	8308	8309	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1357	8310	8311	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1358	8320	8321	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1359	8322	8323	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1360	8324	8325	6	6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1361	8326	8327	7	7	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1362	8328	8330	28	28	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1363	8331	8332	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1364	8333	8334	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1365	8335	8340	Denko	denko	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1366	8341	8343	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1367	8344	8348	1960	1960	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1368	8349	8357	reported	report	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1369	8358	8362	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1370	8363	8365	12	12	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1371	8365	8366	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1372	8367	8369	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1373	8370	8378	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1374	8387	8391	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1375	8392	8394	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1376	8395	8398	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1377	8399	8417	hepatosplenomegaly	hepatosplenomegaly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1378	8418	8419	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1379	8420	8422	29	29	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1380	8423	8424	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1381	8425	8426	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1382	8427	8432	Other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1383	8433	8440	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1384	8441	8445	done	do	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1385	8454	8456	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1386	8457	8460	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1387	8461	8465	1960	1960	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1388	8465	8467	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1389	8468	8472	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1390	8473	8482	confirmed	confirm	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1391	8483	8495	hepatomegaly	hepatomegaly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1392	8496	8498	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1393	8499	8501	18	18	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1394	8501	8502	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1395	8502	8504	20	20	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1396	8504	8505	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1397	8506	8508	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1398	8517	8525	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1399	8526	8530	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1400	8531	8533	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1401	8534	8535	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1402	8536	8538	30	30	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1403	8539	8541	31	31	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1404	8542	8543	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1405	8544	8545	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1406	8546	8548	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1407	8549	8553	1970	1970	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1408	8553	8554	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1409	8555	8561	Whaley	whaley	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1410	8562	8570	reported	report	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1411	8571	8576	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1412	8585	8592	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1413	8593	8595	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1414	8596	8597	6	6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1415	8597	8598	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1416	8599	8601	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1417	8602	8610	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1418	8611	8615	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1419	8616	8618	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1420	8619	8622	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1421	8623	8632	mentioned	mention	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1422	8633	8635	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1423	8644	8655	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1424	8656	8660	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1425	8661	8679	anti-mitochondrial	anti-mitochondrial	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1426	8680	8690	antibodies	antibody	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1427	8691	8692	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1428	8693	8694	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1429	8695	8696	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1430	8697	8698	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1431	8699	8701	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1432	8710	8714	1986	1986	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1433	8714	8715	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1434	8716	8723	Tsianos	tsiano	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1435	8724	8727	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1436	8728	8738	co-workers	co-worker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1437	8739	8748	described	describe	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1438	8749	8751	22	22	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1439	8752	8754	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1440	8755	8763	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1441	8764	8768	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1442	8777	8793	gastrointestinal	gastrointestinal	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1443	8794	8807	complications	complication	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1444	8807	8808	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1445	8809	8815	called	call	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1446	8816	8820	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1447	8821	8822	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1448	8823	8828	large	large	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1449	8829	8835	cohort	cohort	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1450	8835	8836	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1451	8845	8849	only	only	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1452	8850	8853	two	two	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1453	8854	8862	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1454	8863	8866	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1455	8867	8872	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1456	8873	8880	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1457	8880	8881	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1458	8882	8886	each	each	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1459	8887	8891	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1460	8892	8899	chronic	chronic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1461	8908	8914	active	active	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1462	8915	8924	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1463	8925	8926	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1464	8927	8928	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1465	8929	8930	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1466	8931	8932	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1467	8933	8938	Other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1468	8939	8946	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1469	8947	8951	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1470	8952	8960	reported	report	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1471	8969	8977	variable	variable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1472	8978	8988	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1473	8989	8990	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1474	8991	8992	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1475	8993	8995	28	28	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1476	8996	8997	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1477	8998	9001	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1478	9002	9011	different	different	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1479	9020	9037	histopathological	histopathological	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1480	9038	9046	findings	finding	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1481	9047	9049	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1482	9050	9055	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1483	9056	9064	biopsies	biopsy	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1484	9065	9072	ranging	rang	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1485	9073	9077	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1486	9086	9097	cholestatic	cholestatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1487	9098	9103	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1488	9104	9110	damage	damage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1489	9111	9112	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1490	9112	9117	stage	stage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1491	9118	9119	I	i	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1492	9120	9127	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1493	9128	9135	biliary	biliary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1494	9144	9153	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1495	9153	9154	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1496	9155	9157	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1497	9158	9165	chronic	chronic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1498	9166	9172	active	active	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1499	9173	9182	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1500	9183	9186	due	due	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1501	9187	9189	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1502	9190	9199	hepatitis	hepatitis	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1503	9200	9201	C	c	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1504	9210	9215	virus	virus	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1505	9215	9216	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1506	9225	9227	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1507	9228	9231	our	our	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1508	9232	9237	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1509	9237	9238	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1510	9239	9244	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1511	9245	9252	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1512	9253	9256	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1513	9257	9267	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1514	9268	9272	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1515	9273	9278	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1516	9287	9299	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1517	9300	9314	manifestations	manifestation	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1518	9315	9317	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1519	9318	9319	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1520	9319	9320	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1521	9320	9322	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1522	9322	9323	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1523	9324	9336	specifically	specifically	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1524	9337	9342	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1525	9351	9360	affecting	affect	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1526	9361	9365	lung	lung	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1527	9365	9366	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1528	9367	9373	kidney	kidney	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1529	9374	9377	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1530	9378	9383	blood	blood	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1531	9384	9389	cells	cell	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1532	9389	9390	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1533	9391	9396	Those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1534	9397	9405	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1535	9406	9410	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1536	9419	9430	serological	serological	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1537	9431	9439	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1538	9440	9442	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1539	9443	9451	systemic	systemic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1540	9452	9464	inflammation	inflammation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1541	9464	9465	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1542	9466	9468	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1543	9469	9474	shown	show	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1544	9475	9477	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1545	9486	9488	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1546	9489	9497	elevated	elevated	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1547	9498	9511	sedimentation	sedimentation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1548	9512	9516	rate	rate	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1549	9516	9517	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1550	9518	9522	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1551	9523	9527	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1552	9528	9534	likely	likely	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1553	9535	9537	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1554	9538	9542	have	have	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1555	9551	9556	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1556	9557	9561	test	test	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1557	9562	9575	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1558	9575	9576	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1559	9577	9581	Also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1560	9581	9582	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1561	9583	9586	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1562	9587	9595	presence	presence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1563	9596	9598	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1564	9599	9600	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1565	9601	9609	positive	positive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1566	9618	9623	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1567	9623	9626	ENA	ena	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1568	9627	9637	correlated	correlate	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1569	9638	9648	positively	positively	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1570	9649	9653	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1571	9654	9661	hepatic	hepatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1572	9662	9669	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1573	9669	9670	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1574	9671	9673	An	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1575	9682	9693	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1576	9694	9696	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1577	9697	9700	ENA	ena	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1578	9701	9709	response	response	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1579	9710	9714	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1580	9715	9720	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1581	9721	9728	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1582	9729	9732	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1583	9733	9737	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1584	9746	9755	described	describe	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1585	9756	9758	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1586	9759	9767	children	child	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1587	9768	9772	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1588	9773	9783	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1589	9784	9793	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1590	9793	9794	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1591	9795	9800	where	where	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1592	9809	9814	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1593	9814	9826	ENA-positive	ena-positive	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1594	9827	9835	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1595	9836	9848	demonstrated	demonstrate	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1596	9849	9853	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1597	9854	9860	severe	severe	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1598	9861	9866	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1599	9875	9879	test	test	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1600	9880	9893	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1601	9894	9898	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1602	9899	9904	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1603	9905	9908	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1604	9909	9913	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1605	9914	9919	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1606	9919	9931	ENA-negative	ena-negative	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1607	9932	9933	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1608	9942	9944	32	32	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1609	9945	9946	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1610	9947	9948	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1611	9949	9951	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1612	9952	9959	another	another	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1613	9960	9965	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1614	9965	9966	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1615	9967	9968	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1616	9969	9971	15	15	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1617	9972	9973	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1618	9974	9976	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1619	9977	9985	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1620	9986	9990	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1621	9991	9998	various	various	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1622	10007	10014	chronic	chronic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1623	10015	10020	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1624	10021	10029	diseases	disease	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1625	10030	10034	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1626	10035	10040	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1627	10041	10043	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1628	10044	10046	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1629	10047	10052	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1630	10052	10055	RNP	rnp	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1631	10056	10064	positive	positive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1632	10065	10066	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1633	10075	10077	33	33	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1634	10078	10079	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1635	10080	10081	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1636	10090	10094	With	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1637	10095	10111	etiopathogenesis	etiopathogenesis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1638	10112	10114	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1639	10115	10116	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1640	10116	10117	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1641	10117	10119	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1642	10120	10125	still	still	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1643	10126	10128	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1644	10129	10133	open	open	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1645	10134	10142	question	question	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1646	10143	10144	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1647	10153	10155	34	34	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1648	10156	10157	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1649	10158	10159	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1650	10160	10161	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1651	10162	10170	possible	possible	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1652	10171	10175	role	role	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1653	10176	10178	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1654	10179	10188	hepatitis	hepatitis	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1655	10189	10190	C	c	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1656	10191	10196	virus	virus	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1657	10197	10198	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1658	10198	10201	HCV	hcv	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1659	10201	10202	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1660	10203	10206	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1661	10207	10212	drawn	draw	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1662	10221	10230	attention	attention	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1663	10230	10231	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1664	10232	10238	Recent	recent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1665	10239	10246	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1666	10247	10251	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1667	10252	10261	mentioned	mention	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1668	10262	10265	HCV	hcv	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1669	10266	10275	incidence	incidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1670	10276	10278	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1671	10287	10295	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1672	10296	10300	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1673	10301	10302	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1674	10302	10304	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1675	10305	10312	ranging	rang	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1676	10313	10317	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1677	10318	10320	14	14	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1678	10320	10321	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1679	10321	10323	19	19	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1680	10323	10324	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1681	10325	10326	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1682	10327	10329	11	11	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1683	10330	10332	12	12	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1684	10333	10335	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1685	10336	10338	18	18	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1686	10339	10341	21	21	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1687	10342	10343	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1688	10344	10345	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1689	10354	10364	Phenotypic	phenotypic	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1690	10365	10381	characterization	characterization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1691	10382	10384	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1692	10385	10388	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1693	10389	10394	minor	minor	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1694	10395	10403	salivary	salivary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1695	10404	10410	glands	gland	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1696	10419	10423	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1697	10424	10444	immunohistochemistry	immunohistochemistry	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1698	10445	10447	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1699	10448	10456	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1700	10457	10461	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1701	10462	10471	hepatitis	hepatitis	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1702	10472	10473	C	c	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1703	10482	10487	virus	virus	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1704	10488	10497	infection	infection	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1705	10498	10501	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1706	10501	10502	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1707	10502	10504	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1708	10505	10506	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1709	10506	10507	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1710	10507	10509	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1711	10510	10513	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1712	10514	10519	given	give	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1713	10520	10531	conflicting	conflict	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1714	10532	10539	results	result	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1715	10540	10541	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1716	10550	10552	14	14	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1717	10553	10555	15	15	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1718	10556	10557	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1719	10558	10562	Some	some	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1720	10563	10570	reports	report	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1721	10571	10578	mention	mention	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1722	10579	10583	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1723	10584	10587	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1724	10588	10596	salivary	salivary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1725	10597	10602	gland	gland	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1726	10611	10619	findings	finding	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1727	10620	10623	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1728	10624	10634	strikingly	strikingly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1729	10635	10642	similar	similar	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1730	10643	10645	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1731	10646	10654	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1732	10655	10659	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1733	10660	10665	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1734	10674	10681	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1735	10682	10692	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1736	10693	10697	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1737	10698	10701	HCV	hcv	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1738	10702	10711	infection	infection	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1739	10712	10716	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1740	10717	10719	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1741	10720	10725	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1742	10726	10730	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1743	10739	10740	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1744	10740	10741	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1745	10741	10743	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1746	10744	10745	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1747	10746	10748	12	12	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1748	10749	10750	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1749	10751	10752	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1750	10753	10758	while	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1751	10759	10765	others	other	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1752	10766	10773	mention	mention	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1753	10774	10785	distinctive	distinctive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1754	10786	10797	differences	difference	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1755	10806	10813	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1756	10814	10818	both	both	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1757	10819	10825	groups	group	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1758	10826	10835	regarding	regard	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1759	10836	10841	focus	focus	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1760	10842	10847	score	score	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1761	10847	10848	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1762	10849	10859	expression	expression	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1763	10860	10862	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1764	10871	10878	surface	surface	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1765	10879	10886	markers	marker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1766	10887	10889	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1767	10890	10901	lymphocytes	lymphocyte	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1768	10902	10914	infiltrating	infiltrate	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1769	10915	10918	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1770	10919	10927	salivary	salivary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1771	10936	10942	glands	gland	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1772	10943	10946	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1773	10947	10949	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1774	10950	10960	epithelial	epithelial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1775	10961	10966	cells	cell	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1776	10966	10967	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1777	10968	10970	as	as	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1778	10971	10975	well	well	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1779	10976	10978	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1780	10979	10990	differences	difference	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1781	10991	10993	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1782	11002	11005	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1783	11006	11012	degree	degree	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1784	11013	11015	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1785	11016	11028	inflammation	inflammation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1786	11029	11030	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1787	11031	11033	14	14	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1788	11034	11036	15	15	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1789	11037	11038	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1790	11039	11040	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1791	11041	11051	Transgenic	transgenic	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1792	11052	11056	mice	mouse	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1793	11065	11071	models	model	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1794	11072	11076	that	that	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1795	11077	11082	carry	carry	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1796	11083	11086	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1797	11087	11090	HCV	hcv	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1798	11091	11099	envelope	envelope	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1799	11100	11105	genes	gene	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1800	11106	11113	develop	develop	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1801	11114	11116	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1802	11125	11138	exocrinopathy	exocrinopathy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1803	11139	11148	affecting	affect	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1804	11149	11157	salivary	salivary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1805	11158	11161	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1806	11162	11171	lachrymal	lachrymal	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1807	11172	11178	glands	gland	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1808	11179	11180	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1809	11181	11183	19	19	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1810	11192	11193	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1811	11194	11195	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1812	11196	11206	Expression	expression	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1813	11207	11209	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1814	11210	11222	autoimmunity	autoimmunity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1815	11223	11230	markers	marker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1816	11231	11235	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1817	11236	11241	tends	tend	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1818	11242	11244	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1819	11245	11251	differ	differ	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1820	11260	11267	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1821	11268	11281	HCV-infection	hcv-infection	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1822	11282	11285	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1823	11286	11287	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1824	11287	11288	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1825	11288	11290	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1826	11290	11291	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1827	11292	11300	Positive	positive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1828	11301	11305	ENAs	ena	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1829	11306	11309	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1830	11310	11316	rarely	rarely	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1831	11325	11329	seen	see	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1832	11330	11332	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1833	11333	11345	HCV-patients	hcv-patient	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1834	11345	11346	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1835	11347	11351	Also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1836	11351	11352	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1837	11353	11355	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1838	11356	11360	most	most	JJS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1839	11361	11366	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1840	11367	11372	sicca	sicca	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1841	11373	11381	symptoms	symptom	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1842	11390	11393	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1843	11394	11397	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1844	11398	11405	present	present	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1845	11406	11408	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1846	11409	11420	individuals	individual	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1847	11421	11425	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1848	11426	11429	HCV	hcv	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1849	11430	11432	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1850	11433	11441	compared	compare	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1851	11442	11446	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1852	11455	11458	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1853	11459	11460	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1854	11460	11461	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1855	11461	11463	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1856	11464	11474	population	population	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1857	11474	11475	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1858	11476	11484	Although	although	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1859	11485	11488	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1860	11489	11499	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1861	11500	11502	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1862	11503	11508	viral	viral	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1863	11517	11526	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1864	11527	11534	markers	marker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1865	11535	11537	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1866	11538	11541	our	our	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1867	11542	11547	group	group	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1868	11548	11550	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1869	11551	11559	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1870	11560	11564	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1871	11565	11570	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1872	11579	11586	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1873	11587	11590	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1874	11591	11595	very	very	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1875	11596	11599	low	low	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1876	11600	11603	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1877	11604	11607	did	do	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1878	11608	11611	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1879	11612	11619	account	account	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1880	11620	11623	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1881	11624	11628	most	most	JJS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1882	11629	11631	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1883	11632	11635	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1884	11644	11649	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1885	11650	11654	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1886	11655	11663	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1887	11664	11669	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1888	11670	11678	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1889	11679	11684	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1890	11684	11685	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1891	11686	11691	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1892	11692	11699	markers	marker	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1893	11708	11712	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1894	11713	11716	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1895	11717	11723	sought	seek	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1896	11724	11726	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1897	11727	11728	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1898	11729	11734	small	small	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1899	11735	11745	percentage	percentage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1900	11746	11748	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1901	11749	11754	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1902	11755	11763	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1903	11763	11764	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1904	11765	11767	It	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1905	11776	11778	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1906	11779	11788	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1907	11789	11791	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1908	11792	11796	note	note	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1909	11797	11801	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1910	11802	11805	HCV	hcv	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1911	11806	11813	appears	appear	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1912	11814	11816	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1913	11817	11824	account	account	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1914	11825	11828	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1915	11829	11830	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1916	11839	11847	subgroup	subgroup	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1917	11848	11850	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1918	11851	11859	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1919	11860	11864	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1920	11865	11873	exocrine	exocrine	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1921	11874	11884	complaints	complaint	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1922	11885	11887	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1923	11888	11893	which	which	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1924	11894	11898	half	half	PDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1925	11907	11910	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1926	11911	11916	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1927	11917	11922	might	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1928	11923	11927	meet	meet	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1929	11928	11931	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1930	11932	11942	definition	definition	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1931	11943	11946	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1932	11947	11949	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1933	11950	11959	according	accord	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1934	11960	11962	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1935	11971	11979	European	european	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1936	11980	11983	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1937	11984	11993	Manthorpe	manthorpe	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1938	11994	12002	criteria	criterion	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1939	12002	12003	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1940	12004	12011	However	however	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1941	12011	12012	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1942	12013	12017	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1943	12018	12026	subgroup	subgroup	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1944	12027	12029	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1945	12038	12051	characterized	characterize	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1946	12052	12054	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1947	12055	12058	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1948	12059	12066	absence	absence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1949	12067	12069	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1950	12070	12078	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1951	12079	12093	manifestations	manifestation	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1952	12102	12110	observed	observe	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1953	12111	12113	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1954	12114	12115	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1955	12115	12116	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1956	12116	12118	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1957	12118	12119	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1958	12120	12123	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1959	12124	12127	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1960	12128	12135	absence	absence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1961	12136	12138	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1962	12139	12144	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1963	12144	12146	Ro	ro	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1964	12147	12150	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1965	12151	12156	anti-	anti-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1966	12156	12158	La	la	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1967	12159	12160	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1968	12169	12171	35	35	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1969	12172	12173	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1970	12174	12175	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1971	12184	12186	An	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1972	12187	12195	aberrant	aberrant	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1973	12196	12207	interaction	interaction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1974	12208	12215	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1975	12216	12227	lymphocytes	lymphocyte	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1976	12228	12231	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1977	12240	12249	different	different	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1978	12250	12260	epithelial	epithelial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1979	12261	12268	tissues	tissue	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1980	12269	12272	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1981	12273	12277	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1982	12278	12286	proposed	propose	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1983	12287	12289	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1984	12290	12291	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1985	12300	12309	mechanism	mechanism	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1986	12310	12313	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1987	12314	12317	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1988	12318	12324	damage	damage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1989	12325	12329	seen	see	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1990	12330	12332	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1991	12333	12342	different	different	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1992	12343	12349	organs	organ	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1993	12350	12352	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1994	12353	12354	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1995	12354	12355	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1996	12356	12358	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1997	12367	12368	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1998	12369	12371	36	36	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1999	12372	12373	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2000	12374	12375	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2001	12376	12381	Since	since	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2002	12382	12384	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2003	12385	12388	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2004	12389	12393	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2005	12394	12403	suggested	suggest	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2006	12404	12408	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2007	12409	12412	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2008	12413	12419	target	target	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2009	12420	12426	tissue	tissue	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2010	12435	12443	involved	involve	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2011	12444	12446	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2012	12447	12450	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2013	12451	12461	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2014	12462	12477	histopathologic	histopathologic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2015	12478	12485	lesions	lesion	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2016	12486	12488	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2017	12489	12490	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2018	12490	12491	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2019	12491	12493	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2020	12502	12507	might	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2021	12508	12510	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2022	12511	12514	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2023	12515	12525	epithelium	epithelium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2024	12526	12527	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2025	12528	12530	37	37	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2026	12531	12532	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2027	12533	12534	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2028	12535	12537	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2029	12538	12540	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2030	12541	12552	interesting	interest	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2031	12553	12557	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2032	12558	12561	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2033	12570	12578	findings	finding	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2034	12579	12581	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2035	12582	12585	our	our	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2036	12586	12591	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2037	12592	12597	point	point	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2038	12598	12600	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2039	12601	12604	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2040	12605	12616	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2041	12617	12619	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2042	12620	12625	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2043	12634	12641	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2044	12642	12646	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2045	12647	12656	pulmonary	pulmonary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2046	12657	12660	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2047	12661	12666	renal	renal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2048	12667	12680	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2049	12680	12681	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2050	12682	12685	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2051	12686	12691	which	which	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2052	12700	12703	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2053	12704	12717	characterized	characterize	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2054	12718	12720	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2055	12721	12731	epithelial	epithelial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2056	12732	12738	damage	damage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2057	12739	12740	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2058	12741	12743	38	38	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2059	12744	12746	39	39	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2060	12747	12748	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2061	12749	12750	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2062	12759	12769	Epithelial	epithelial	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2063	12770	12775	cells	cell	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2064	12776	12780	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2065	12781	12785	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2066	12786	12794	proposed	propose	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2067	12795	12797	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2068	12798	12800	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2069	12801	12807	active	active	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2070	12816	12828	participants	participant	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2071	12829	12835	rather	rather	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2072	12836	12840	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2073	12841	12848	passive	passive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2074	12849	12856	targets	target	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2075	12857	12859	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2076	12860	12863	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2077	12864	12871	chronic	chronic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2078	12880	12886	immune	immune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2079	12887	12895	response	response	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2080	12896	12898	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2081	12899	12900	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2082	12900	12901	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2083	12901	12903	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2084	12904	12907	but	but	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2085	12908	12915	further	further	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2086	12916	12923	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2087	12924	12927	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2088	12928	12934	needed	need	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2089	12935	12937	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2090	12946	12955	establish	establish	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2091	12956	12959	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2092	12960	12964	role	role	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2093	12965	12967	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2094	12968	12973	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2095	12974	12984	epithelial	epithelial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2096	12985	12990	cells	cell	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2097	12991	12993	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2098	12994	12997	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2099	13006	13018	pathogenesis	pathogenesis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2100	13019	13021	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2101	13022	13029	hepatic	hepatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2102	13030	13036	damage	damage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2103	13037	13039	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2104	13040	13044	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2105	13045	13052	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2106	13052	13053	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2107	13054	13063	including	include	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2108	13072	13075	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2109	13076	13084	analysis	analysis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2110	13085	13087	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2111	13088	13091	HLA	hlum	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2112	13092	13102	expression	expression	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2113	13103	13106	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2114	13107	13115	cytokine	cytokine	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2115	13116	13125	secretion	secretion	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2116	13134	13141	pattern	pattern	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2117	13142	13144	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2118	13145	13150	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2119	13151	13156	cells	cell	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2120	13156	13157	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2121	13166	13169	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2122	13170	13182	co-existence	co-existence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2123	13183	13185	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2124	13186	13191	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2125	13192	13199	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2126	13200	13203	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2127	13204	13207	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2128	13208	13216	presence	presence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2129	13217	13219	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2130	13228	13239	circulating	circulate	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2131	13240	13244	AMAs	ama	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2132	13245	13247	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2133	13248	13255	Sjögren	sjögren	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2134	13255	13257	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2135	13258	13266	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2136	13267	13271	sera	serum	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2137	13272	13275	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2138	13276	13280	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2139	13289	13296	pointed	point	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2140	13297	13299	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2141	13300	13302	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2142	13303	13312	indicator	indicator	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2143	13313	13317	that	that	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2144	13318	13323	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2145	13324	13333	pathology	pathology	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2146	13334	13339	might	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2147	13340	13342	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2148	13351	13361	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2149	13362	13365	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2150	13366	13373	similar	similar	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2151	13374	13376	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2152	13377	13381	that	that	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2153	13382	13384	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2154	13385	13392	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2155	13393	13400	biliary	biliary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2156	13401	13410	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2157	13419	13420	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2158	13421	13422	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2159	13423	13424	7	7	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2160	13425	13426	8	8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2161	13427	13429	10	10	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2162	13430	13431	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2163	13432	13433	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2164	13434	13436	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2165	13437	13445	previous	previous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2166	13446	13453	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2167	13453	13454	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2168	13455	13456	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2169	13457	13471	pericholangial	pericholangial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2170	13480	13491	lymphocytic	lymphocytic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2171	13492	13504	infiltration	infiltration	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2172	13505	13512	similar	similar	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2173	13513	13515	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2174	13516	13520	that	that	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2175	13521	13526	found	find	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2176	13527	13529	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2177	13530	13535	stage	stage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2178	13536	13537	I	i	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2179	13546	13548	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2180	13549	13556	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2181	13557	13564	biliary	biliary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2182	13565	13574	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2183	13574	13575	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2184	13576	13579	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2185	13580	13584	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2186	13585	13593	reported	report	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2187	13594	13596	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2188	13597	13598	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2189	13598	13599	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2190	13599	13601	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2191	13610	13614	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2192	13615	13623	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2193	13624	13629	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2194	13630	13638	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2195	13639	13644	tests	test	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2196	13645	13647	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2197	13648	13658	positivity	positivity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2198	13659	13662	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2199	13663	13666	AMA	ama	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2200	13667	13668	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2201	13677	13678	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2202	13679	13680	7	7	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2203	13681	13682	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2204	13683	13684	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2205	13685	13687	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2206	13688	13691	our	our	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2207	13692	13698	review	review	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2208	13699	13701	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2209	13702	13707	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2210	13707	13708	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2211	13709	13711	we	we	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2212	13712	13717	found	find	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2213	13718	13730	predominance	predominance	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2214	13731	13733	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2215	13742	13756	hepatocellular	hepatocellular	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2216	13757	13762	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2217	13763	13769	damage	damage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2218	13770	13776	rather	rather	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2219	13777	13781	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2220	13782	13793	cholestatic	cholestatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2221	13802	13809	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2222	13809	13810	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2223	13811	13816	which	which	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2224	13817	13822	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2225	13823	13828	argue	argue	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2226	13829	13836	against	against	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2227	13837	13838	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2228	13839	13847	PBC-type	pbc-type	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2229	13848	13850	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2230	13851	13856	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2231	13865	13871	damage	damage	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2232	13871	13872	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2233	13873	13878	Other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2234	13879	13886	authors	author	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2235	13887	13890	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2236	13891	13899	proposed	propose	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2237	13900	13904	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2238	13905	13907	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2239	13908	13918	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2240	13919	13923	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2241	13932	13935	PBC	pbc	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2242	13936	13942	should	should	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2243	13943	13945	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2244	13946	13956	considered	consider	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2245	13957	13958	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2246	13959	13963	form	form	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2247	13964	13966	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2248	13967	13976	secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2249	13977	13979	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2250	13980	13984	that	that	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2251	13993	14002	resembles	resemble	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2252	14003	14007	more	more	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2253	14008	14011	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2254	14012	14013	""	""	''	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2255	14013	14018	sicca	sicca	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2256	14019	14026	complex	complex	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2257	14026	14027	""	""	''	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2258	14028	14032	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2259	14033	14041	exocrine	exocrine	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2260	14042	14050	features	feature	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2261	14059	14063	seen	see	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2262	14064	14066	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2263	14067	14075	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2264	14076	14080	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2265	14081	14091	rheumatoid	rheumatoid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2266	14092	14101	arthritis	arthritis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2267	14102	14103	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2268	14104	14106	40	40	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2269	14107	14109	41	41	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2270	14110	14111	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2271	14112	14113	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2272	14122	14133	Limitations	limitation	NNPS	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2273	14134	14136	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2274	14137	14140	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2275	14141	14146	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2276	14147	14151	come	come	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2277	14152	14161	primarily	primarily	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2278	14162	14166	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2279	14167	14172	being	be	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2280	14173	14174	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2281	14183	14196	retrospective	retrospective	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2282	14197	14205	analysis	analysis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2283	14205	14206	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2284	14207	14212	Since	since	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2285	14213	14216	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2286	14217	14225	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2287	14226	14230	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2288	14231	14238	studied	study	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2289	14239	14241	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2290	14250	14251	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2291	14252	14260	tertiary	tertiary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2292	14261	14265	care	care	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2293	14266	14274	referral	referral	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2294	14275	14281	center	center	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2295	14281	14282	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2296	14283	14286	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2297	14287	14295	severity	severity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2298	14296	14298	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2299	14299	14302	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2300	14311	14318	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2301	14319	14322	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2302	14323	14326	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2303	14327	14337	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2304	14338	14340	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2305	14341	14344	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2306	14345	14359	manifestations	manifestation	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2307	14360	14365	might	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2308	14366	14368	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2309	14377	14386	different	different	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2310	14387	14391	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2311	14392	14395	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2312	14396	14403	general	general	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2313	14404	14405	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2314	14405	14406	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2315	14406	14408	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2316	14409	14419	population	population	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2317	14419	14420	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2318	14421	14432	Furthermore	furthermore	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2319	14432	14433	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2320	14434	14436	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2321	14445	14449	many	many	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2322	14450	14455	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2323	14455	14456	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2324	14457	14464	Sjögren	sjögren	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2325	14464	14466	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2326	14467	14475	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2327	14476	14485	diagnosis	diagnosis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2328	14486	14489	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2329	14490	14494	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2330	14495	14501	sought	seek	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2331	14510	14517	because	because	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2332	14518	14520	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2333	14521	14530	otherwise	otherwise	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2334	14531	14542	unexplained	unexplain	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2335	14543	14555	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2336	14556	14564	features	feature	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2337	14564	14565	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2338	14574	14579	While	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2339	14580	14582	we	we	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2340	14583	14588	could	could	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2341	14589	14592	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2342	14593	14597	find	find	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2343	14598	14600	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2344	14601	14612	association	association	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2345	14613	14620	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2346	14621	14624	use	use	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2347	14625	14627	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2348	14636	14642	NSAIDS	nsaid	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2349	14643	14645	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2350	14646	14651	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2351	14652	14663	medications	medication	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2352	14664	14667	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2353	14668	14678	prevalence	prevalence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2354	14679	14681	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2355	14682	14687	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2356	14696	14704	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2357	14705	14710	tests	test	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2358	14711	14724	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2359	14724	14725	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2360	14726	14729	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2361	14730	14735	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2362	14736	14742	design	design	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2363	14743	14746	did	do	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2364	14747	14750	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2365	14759	14764	allow	allow	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2366	14765	14767	us	us	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2367	14768	14770	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2368	14771	14778	exclude	exclude	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2369	14779	14782	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2370	14783	14794	possibility	possibility	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2371	14795	14797	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2372	14798	14814	over-the-counter	over-the-counter	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2373	14823	14824	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2374	14824	14827	OTC	otc	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2375	14827	14828	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2376	14829	14839	medication	medication	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2377	14840	14843	use	use	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2378	14844	14848	that	that	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2379	14849	14854	could	could	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2380	14855	14859	have	have	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2381	14860	14868	affected	affect	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2382	14869	14872	LFT	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2383	14872	14874	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2384	14883	14894	measurement	measurement	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2385	14894	14895	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2386	14896	14900	Drug	drug	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2387	14901	14909	toxicity	toxicity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2388	14910	14912	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2389	14913	14922	certainly	certainly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2390	14923	14925	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2391	14926	14935	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2392	14936	14942	factor	factor	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2393	14951	14953	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2394	14954	14956	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2395	14957	14967	considered	consider	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2396	14967	14968	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2397	14969	14976	However	however	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2398	14976	14977	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2399	14978	14983	given	give	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2400	14984	14988	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2401	14989	14993	most	most	JJS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2402	14994	15002	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2403	15003	15006	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2404	15015	15025	persistent	persistent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2405	15026	15032	rather	rather	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2406	15033	15037	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2407	15038	15050	intermittent	intermittent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2408	15051	15064	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2409	15065	15067	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2410	15068	15072	LFTs	lft	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2411	15081	15084	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2412	15085	15089	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2413	15090	15093	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2414	15094	15097	use	use	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2415	15098	15100	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2416	15101	15112	hepatotoxic	hepatotoxic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2417	15113	15118	drugs	drug	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2418	15119	15122	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2419	15123	15126	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2420	15127	15135	elicited	elicit	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2421	15136	15138	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2422	15147	15150	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2423	15151	15159	majority	majority	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2424	15160	15162	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2425	15163	15171	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2426	15172	15176	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2427	15177	15182	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2428	15183	15196	abnormalities	abnormality	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2429	15196	15197	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2430	15198	15199	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2431	15200	15205	toxic	toxic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2432	15214	15220	effect	effect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2433	15221	15223	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2434	15224	15235	medications	medication	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2435	15236	15241	could	could	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2436	15242	15245	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2437	15246	15248	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2438	15249	15260	established	establish	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2439	15260	15261	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2440	15284	15295	Conclusions	conclusion	NNP	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
2441	15304	15309	Based	base	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2442	15310	15312	on	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2443	15313	15316	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2444	15317	15324	results	result	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2445	15325	15327	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2446	15328	15332	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2447	15333	15338	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2448	15338	15339	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2449	15340	15342	we	we	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2450	15343	15351	consider	consider	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2451	15352	15356	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2452	15357	15359	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2453	15368	15378	evaluation	evaluation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2454	15379	15382	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2455	15383	15391	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2456	15392	15395	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2457	15396	15407	serological	serological	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2458	15408	15416	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2459	15417	15419	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2460	15420	15425	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2461	15434	15441	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2462	15442	15448	should	should	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2463	15449	15451	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2464	15452	15456	done	do	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2465	15457	15459	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2466	15460	15465	every	every	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2467	15466	15473	patient	patient	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2468	15474	15478	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2469	15479	15480	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2470	15480	15481	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2471	15481	15483	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2472	15483	15484	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2473	15493	15505	particularly	particularly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2474	15506	15508	if	if	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2475	15509	15514	there	there	EX	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2476	15515	15517	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2477	15518	15526	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2478	15527	15529	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2479	15530	15535	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2480	15536	15548	non-exocrine	non-exocrine	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2481	15557	15570	complications	complication	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2482	15571	15573	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2483	15574	15585	serological	serological	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2484	15586	15594	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2485	15595	15597	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2486	15598	15606	systemic	systemic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2487	15615	15627	inflammation	inflammation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2488	15627	15628	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2489	15629	15637	Although	although	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2490	15638	15640	no	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2491	15641	15646	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2492	15647	15656	diagnosis	diagnosis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2493	15657	15667	explaining	explain	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2494	15668	15673	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2495	15682	15689	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2496	15690	15693	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2497	15694	15696	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2498	15697	15702	found	find	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2499	15702	15703	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2500	15704	15707	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2501	15708	15717	disorders	disorder	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2502	15718	15721	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2503	15722	15727	which	which	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2504	15728	15737	treatment	treatment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2505	15746	15751	might	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2506	15752	15754	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2507	15755	15765	beneficial	beneficial	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2508	15766	15767	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2509	15767	15771	e.g.	e.g.	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2510	15772	15790	immunosuppressants	immunosuppressant	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2511	15791	15794	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2512	15795	15805	autoimmune	autoimmune	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2513	15814	15823	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2514	15823	15824	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2515	15825	15841	interferon-alpha	interferon-alpha	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2516	15842	15845	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2517	15846	15851	viral	viral	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2518	15852	15861	hepatitis	hepatitis	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2519	15861	15862	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2520	15871	15885	ursodeoxycolic	ursodeoxycolic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2521	15886	15890	acid	acid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2522	15891	15894	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2523	15895	15902	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2524	15903	15910	biliary	biliary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2525	15911	15920	cirrhosis	cirrhosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2526	15920	15921	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2527	15922	15929	warrant	warrant	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2528	15938	15939	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2529	15940	15948	diligent	diligent	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2530	15949	15955	search	search	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2531	15956	15958	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2532	15959	15962	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2533	15963	15968	cases	case	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2534	15969	15971	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2535	15972	15973	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2536	15973	15974	°	°	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2537	15974	15976	SS	ss	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2538	15977	15981	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2539	15982	15990	abnormal	abnormal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2540	15991	15996	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2541	16005	16013	function	function	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2542	16013	16014	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2543	16037	16046	Competing	compete	VBG	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
2544	16047	16056	interests	interest	NNS	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
2545	16065	16069	None	none	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2546	16069	16070	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2547	16093	16100	Authors	author	NNP	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
2548	16100	16101	'	'	POS	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
2549	16102	16115	contributions	contribution	NNS	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
2550	16124	16128	Both	both	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2551	16129	16136	authors	author	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2552	16137	16148	contributed	contribute	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2553	16149	16156	equally	equally	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2554	16157	16159	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2555	16160	16163	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2556	16164	16169	paper	paper	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2557	16169	16170	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_

